But for PTPN9, which appears to be a tumor suppressor, leads to decreased glioma cell viability by reducing the phosphorylation of EGFR and cooperating with BRAF (V600E) inhibitors to restrain MAPK and AKT signaling (101). Here, AKT1 is linked to neoplasm.